Ekspression af SOX0 forudsiger tilbagefald af stadium II colon cancer patienter

Maiken Lise Marcker Espersen, Dorte Linnemann, Ib Jarle Christensen, Mahdi Alamili, Jesper T. Troelsen, Estrid Høgdall

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The aim of this study was to investigate if the protein expression of Sex-determining region y-box 9 (SOX9) in primary tumors could predict relapse of stage II colon cancer patients.144 patients with stage II primary colon cancer were retrospectively enrolledin the study. SOX9 expression was evaluated by immunohistochemistry and mismatch repair status was assessed by both immunohistochemistry and promoter hyper-methylation assay. High SOX9 expression at the invasive front was significantly associated with lower risk of relapse when including the SOX9 expression as a continuous variable (from low to high expression) in univariate (HR: 0.73; 95% CI: 0.56-0.94; p=0.01) and multivariate cox proportional hazards analysis (HR: 0.75; 95% CI: 0.58-0.96; p=0.02) adjusting for mismatch repair deficiency and histopathological risk factors. Conversely, low SOX9 expression at the invasive front was significantly associated with high risk of relapse, when including SOX9 expression dichotomous variable, in univariate (HR: 2.32; 95% CI: 1.14-4.69; p=0.02) and multivariate analysis (HR: 2.32; 95% CI: 1.14-4.69; p=0.02) adjusting for histopathological risk factors and mismatch repair deficiency. In conclusion high levels of SOX9 of primary stage II colon tumors predict low riskof relapse whereas low levels of SOX9 predict high risk of relapse. SOX9 may have an important value as a biomarker when evaluating risk of relapse for personalized treatment.
Bidragets oversatte titelEkspression af SOX0 forudsiger tilbagefald af stadium II colon cancer patienter
OriginalsprogEngelsk
TidsskriftHuman Pathology
Vol/bind52
Sider (fra-til)38–46
ISSN0046-8177
DOI
StatusUdgivet - 2016

Emneord

  • Relaps
  • colon cancer
  • biomarkør
  • SOX9

Citer dette

Espersen, M. L. M., Linnemann, D., Christensen, I. J., Alamili, M., T. Troelsen, J., & Høgdall, E. (2016). SOX9 Expression Predicts Relapse of Stage II Colon Cancer Patients. Human Pathology, 52, 38–46. https://doi.org/10.1016/j.humpath.2015.12.026
Espersen, Maiken Lise Marcker ; Linnemann, Dorte ; Christensen, Ib Jarle ; Alamili, Mahdi ; T. Troelsen, Jesper ; Høgdall, Estrid. / SOX9 Expression Predicts Relapse of Stage II Colon Cancer Patients. I: Human Pathology. 2016 ; Bind 52. s. 38–46.
@article{11c82dc88c83446da6e9f05247ae3c04,
title = "SOX9 Expression Predicts Relapse of Stage II Colon Cancer Patients",
abstract = "The aim of this study was to investigate if the protein expression of Sex-determining region y-box 9 (SOX9) in primary tumors could predict relapse of stage II colon cancer patients.144 patients with stage II primary colon cancer were retrospectively enrolledin the study. SOX9 expression was evaluated by immunohistochemistry and mismatch repair status was assessed by both immunohistochemistry and promoter hyper-methylation assay. High SOX9 expression at the invasive front was significantly associated with lower risk of relapse when including the SOX9 expression as a continuous variable (from low to high expression) in univariate (HR: 0.73; 95{\%} CI: 0.56-0.94; p=0.01) and multivariate cox proportional hazards analysis (HR: 0.75; 95{\%} CI: 0.58-0.96; p=0.02) adjusting for mismatch repair deficiency and histopathological risk factors. Conversely, low SOX9 expression at the invasive front was significantly associated with high risk of relapse, when including SOX9 expression dichotomous variable, in univariate (HR: 2.32; 95{\%} CI: 1.14-4.69; p=0.02) and multivariate analysis (HR: 2.32; 95{\%} CI: 1.14-4.69; p=0.02) adjusting for histopathological risk factors and mismatch repair deficiency. In conclusion high levels of SOX9 of primary stage II colon tumors predict low riskof relapse whereas low levels of SOX9 predict high risk of relapse. SOX9 may have an important value as a biomarker when evaluating risk of relapse for personalized treatment.",
keywords = "Relaps, colon cancer, biomark{\o}r, SOX9, Relaps, colon cancer, biomark{\o}r, SOX9",
author = "Espersen, {Maiken Lise Marcker} and Dorte Linnemann and Christensen, {Ib Jarle} and Mahdi Alamili and {T. Troelsen}, Jesper and Estrid H{\o}gdall",
year = "2016",
doi = "10.1016/j.humpath.2015.12.026",
language = "English",
volume = "52",
pages = "38–46",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B.Saunders Co.",

}

Espersen, MLM, Linnemann, D, Christensen, IJ, Alamili, M, T. Troelsen, J & Høgdall, E 2016, 'SOX9 Expression Predicts Relapse of Stage II Colon Cancer Patients' Human Pathology, bind 52, s. 38–46. https://doi.org/10.1016/j.humpath.2015.12.026

SOX9 Expression Predicts Relapse of Stage II Colon Cancer Patients. / Espersen, Maiken Lise Marcker; Linnemann, Dorte; Christensen, Ib Jarle; Alamili, Mahdi; T. Troelsen, Jesper; Høgdall, Estrid.

I: Human Pathology, Bind 52, 2016, s. 38–46.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - SOX9 Expression Predicts Relapse of Stage II Colon Cancer Patients

AU - Espersen, Maiken Lise Marcker

AU - Linnemann, Dorte

AU - Christensen, Ib Jarle

AU - Alamili, Mahdi

AU - T. Troelsen, Jesper

AU - Høgdall, Estrid

PY - 2016

Y1 - 2016

N2 - The aim of this study was to investigate if the protein expression of Sex-determining region y-box 9 (SOX9) in primary tumors could predict relapse of stage II colon cancer patients.144 patients with stage II primary colon cancer were retrospectively enrolledin the study. SOX9 expression was evaluated by immunohistochemistry and mismatch repair status was assessed by both immunohistochemistry and promoter hyper-methylation assay. High SOX9 expression at the invasive front was significantly associated with lower risk of relapse when including the SOX9 expression as a continuous variable (from low to high expression) in univariate (HR: 0.73; 95% CI: 0.56-0.94; p=0.01) and multivariate cox proportional hazards analysis (HR: 0.75; 95% CI: 0.58-0.96; p=0.02) adjusting for mismatch repair deficiency and histopathological risk factors. Conversely, low SOX9 expression at the invasive front was significantly associated with high risk of relapse, when including SOX9 expression dichotomous variable, in univariate (HR: 2.32; 95% CI: 1.14-4.69; p=0.02) and multivariate analysis (HR: 2.32; 95% CI: 1.14-4.69; p=0.02) adjusting for histopathological risk factors and mismatch repair deficiency. In conclusion high levels of SOX9 of primary stage II colon tumors predict low riskof relapse whereas low levels of SOX9 predict high risk of relapse. SOX9 may have an important value as a biomarker when evaluating risk of relapse for personalized treatment.

AB - The aim of this study was to investigate if the protein expression of Sex-determining region y-box 9 (SOX9) in primary tumors could predict relapse of stage II colon cancer patients.144 patients with stage II primary colon cancer were retrospectively enrolledin the study. SOX9 expression was evaluated by immunohistochemistry and mismatch repair status was assessed by both immunohistochemistry and promoter hyper-methylation assay. High SOX9 expression at the invasive front was significantly associated with lower risk of relapse when including the SOX9 expression as a continuous variable (from low to high expression) in univariate (HR: 0.73; 95% CI: 0.56-0.94; p=0.01) and multivariate cox proportional hazards analysis (HR: 0.75; 95% CI: 0.58-0.96; p=0.02) adjusting for mismatch repair deficiency and histopathological risk factors. Conversely, low SOX9 expression at the invasive front was significantly associated with high risk of relapse, when including SOX9 expression dichotomous variable, in univariate (HR: 2.32; 95% CI: 1.14-4.69; p=0.02) and multivariate analysis (HR: 2.32; 95% CI: 1.14-4.69; p=0.02) adjusting for histopathological risk factors and mismatch repair deficiency. In conclusion high levels of SOX9 of primary stage II colon tumors predict low riskof relapse whereas low levels of SOX9 predict high risk of relapse. SOX9 may have an important value as a biomarker when evaluating risk of relapse for personalized treatment.

KW - Relaps

KW - colon cancer

KW - biomarkør

KW - SOX9

KW - Relaps

KW - colon cancer

KW - biomarkør

KW - SOX9

U2 - 10.1016/j.humpath.2015.12.026

DO - 10.1016/j.humpath.2015.12.026

M3 - Journal article

VL - 52

SP - 38

EP - 46

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -